Sue Hartigan <[EMAIL PROTECTED]> writes:
Hi Terry:
I found the National Cancer Research page, and here is what they said,
hope that it helps:
National Cancer
Institute
May 4, 1998
FOR RESPONSE
TO INQUIRIES
NCI Press Office
(301) 496-6641
Backgrounder
NCI Statement on Animal Studies of
Endostatin and Angiostatin
The National Cancer Institute (NCI) is
encouraged by results from animal studies that
suggest that compounds isolated by researchers
in the laboratory of Judah Folkman, M.D., of
Children's Hospital and Harvard Medical School
in Boston, Mass., may be potent anti-cancer
agents. NCI has made it a high priority to move
research forward on these compounds,
endostatin and angiostatin, so that clinical trials in
humans can begin. It is important to note that
such human studies will not begin for many
months, most likely not until 1999. Once testing
has begun, the compounds, which are
anti-angiogenesis agents, must be tested
separately for safety and efficacy in humans
before they can be tested together.
Production of these compounds is one part of
the process that must take place over the next
several months. At this time, it is not possible to
produce the large quantities of endostatin or
angiostatin necessary for human trials. NCI is
working with Entremed, Inc., on production
issues for endostatin and with Bristol-Myers
Squibb Co., on production issues for angiostatin.
It is very important to emphasize that while the
possibilities raised by these studies in mice are
encouragaing, it is not known whether endostatin
or angiostatin will be effective in people with
cancer.
Clinical trials of other anti-angiogenesis agents
are under way both by individual drug
companies and by NCI. Patients interested in
information about ongoing trials listed in NCI's
PDQ database can contact the NCI's Cancer
Information Service at 1-800-4-CANCER or
search PDQ themselves via the Internet
(http://cancertrials.nci.nih.gov -- under "more"
choose Introduction, then choose "finding
specific trials").
--
Two rules in life:
1. Don't tell people everything you know.
2.
Subscribe/Unsubscribe, email: [EMAIL PROTECTED]
In the body of the message enter: subscribe/unsubscribe law-issues
